1. Introduction {#sec1-jcm-09-02342}
===============

Fluoropyrimidine drugs (FPs), including 5-fluorouracil (5-FU) and its oral prodrugs tegafur, capecitabine, and doxifluridine, are widely used in the treatment of solid tumors in the gastrointestinal tract, breast, liver, lung, head, and neck \[[@B1-jcm-09-02342],[@B2-jcm-09-02342],[@B3-jcm-09-02342]\]. FP-based treatments have a narrow therapeutic index, which has led to severe adverse effects in approximately 30% of cancer patients, including mucositis, diarrhea, neutropenia, thrombocytopenia, and hand--foot syndrome \[[@B4-jcm-09-02342],[@B5-jcm-09-02342],[@B6-jcm-09-02342],[@B7-jcm-09-02342],[@B8-jcm-09-02342]\]. Additionally, severe treatment toxicities could lead to treatment interruption, which increases the subsequent risk of therapeutic failure as well as patient death \[[@B9-jcm-09-02342]\].

Genetic polymorphisms of thymidylate synthase (TYMS), methylene tetrahydrofolate reductase (MTHFR), and miR-27a are associated with the development of severe toxicities as well as treatment resistance; however, FP-related toxicity is mainly dependent on FP catabolism. Over 80% of an administered dose of 5-FU is rapidly degraded by three consecutive enzymes belonging to the endogenous pyrimidine, uracil, and thymine catabolic pathways ([Figure 1](#jcm-09-02342-f001){ref-type="fig"}), the only known 5-FU in vivo degradation pathway. Initially, the rate-limiting enzyme dihydropyrimidine dehydrogenase (DPD, EC 1.3.1.2), mainly found in the liver, catalyzes the reduction of 5-FU to dihydro-5-fluorouracil (FUH~2~). Subsequently, dihydropyrimidinase (DHP, EC 3.5.2.2) catalyzes the hydrolytic ring opening of FUH~2~ to form fluoro-β-ureidopropionic acid (FUPA). Even though DPD and DHP catalysis is reversible, the positive reaction is dominant in vivo \[[@B10-jcm-09-02342],[@B11-jcm-09-02342],[@B12-jcm-09-02342],[@B13-jcm-09-02342],[@B14-jcm-09-02342],[@B15-jcm-09-02342]\]. Lastly, β-ureidopropionase (β-UP, EC 3.5.1.6) catalyzes the hydrolysis of FUPA to fluoro-β-alanine. The three enzymes (DPD, DHP, and β-UP) are encoded by the *DPYD*, *DPYS*, and *UPB1* genes, respectively \[[@B16-jcm-09-02342],[@B17-jcm-09-02342],[@B18-jcm-09-02342]\].

Decreased DPD and DHP enzymatic activities have been linked to genetic polymorphisms identified in patients with severe FP-related toxicities; for each causative polymorphism, the reduction in activity is caused mainly by the substitution or deletion of amino acids \[[@B19-jcm-09-02342],[@B20-jcm-09-02342],[@B21-jcm-09-02342]\]. However, the relationship between β-UP activity and the development of FP-related toxicity is still unknown. To date, the specific effects of previously identified polymorphisms on enzymatic function are largely unknown. Only four *DPYD* variants (c.1905 + 1G \> A (IVS14 + 1G \> A, *DPYD\*2A*); c.1679T \> G (*DPYD\*13*, p.I560S); c.1129 − 5923C \> G /hapB3; and c.2846A \> T (p.D949V)) have been characterized as predictive markers for FP-related toxicity in Caucasians \[[@B22-jcm-09-02342]\]. However, significant racial and individual differences in polymorphism location and frequency make it challenging to safely extrapolate the clinical data and institute regional guidelines from one population to another. Thus, it is necessary to further clarify the effects of genetic polymorphisms in an attempt to establish their effect on in vivo enzymatic function. For example, before FP administration, PCR-Restriction Fragment Length Polymorphism (RFLP) analysis, Sanger sequencing, and next-generation sequencing analysis are often used for detecting genetic polymorphisms and establishing patient risk. Moreover, hepatic DPD activity, and thus DPD deficiency incidence, can be predicted by assessing peripheral blood mononuclear cell (PBMC) DPD activity. However, to date, there are no established methods to quantify DHP and β-UP activity clinically.

The most direct method to understand the effect of the genetic polymorphisms of these enzymes on FP pharmacokinetics is to measure metabolite concentrations in blood and urine from subjects with the respective genotypes after FP administration. However, in vivo testing is highly invasive due to continuous blood sampling and poses a considerable risk of FP-related toxicity. Additionally, as the variants of interest are mainly low-frequency polymorphisms, the recruitment of an adequate subject pool to obtain statistically significant data is considerably difficult. While pyrimidine metabolites in blood and urine have been previously quantified to assess enzymatic activity in vivo, these have yielded contradictory results \[[@B23-jcm-09-02342],[@B24-jcm-09-02342]\].

In contrast, in vitro testing using heterologous expression systems has yielded reproducible results using non-invasive methods to facilitate enzymatic activity assessment \[[@B25-jcm-09-02342]\]. Amongst these, several in vitro FP analyses using *Escherichia coli* or mammalian cells have been reported. While other in vitro techniques have been used to evaluate genetic polymorphisms including gene expression profiling, in this review, we focus on the in vitro analysis of the FP-metabolizing enzymes: DPD, DHP, and β-UP, thus providing further information to aid in the application of genetic testing in a clinical setting in light of recent novel insights.

2. Dihydropyrimidine Dehydrogenase (DPD) {#sec2-jcm-09-02342}
========================================

DPD, the rate-limiting enzyme of the pyrimidine degradation pathway, catalyzes the reduction of 5-FU and uracil to FUH~2~ and dihydrouracil (UH~2~). The DPD gene (*DPYD*) is expressed in most human tissues, but the expression level is highest in the liver and PBMCs \[[@B26-jcm-09-02342]\]. Located on chromosome 1p21, human *DPYD* is comprised of 23 exons and features a 3078 bp open reading frame, encoding a polypeptide containing 1025 amino acid residues \[[@B27-jcm-09-02342]\].

DPD deficiency is an autosomal recessive disorder first reported in a child with neurological symptoms by Bakkeren et al., which was characterized by the accumulation of uracil and thymine in urine, blood, and cerebrospinal fluid \[[@B28-jcm-09-02342]\]. The clinical symptoms include convulsions, autism, microcephaly, growth impairment, and intellectual disability, although asymptomatic cases have also been reported \[[@B29-jcm-09-02342],[@B30-jcm-09-02342],[@B31-jcm-09-02342]\]. The frequency of DPD-deficient patients varies greatly across world populations. While Caucasian frequencies range from 3--5% for partial deficiency and 0.2% for complete deficiency, it is estimated to be extremely rare in Asians \[[@B32-jcm-09-02342],[@B33-jcm-09-02342]\]. In the case of asymptomatic DPD deficiency, there is a considerable risk of FP accumulation during treatment, including 5-FU, which could lead to severe toxicity in patients \[[@B34-jcm-09-02342],[@B35-jcm-09-02342],[@B36-jcm-09-02342]\]. Therefore, it is imperative to diagnose DPD deficiency before chemotherapy administration, even in cases with no prior clinical evidence of this condition.

Of the three metabolic enzymes, *DPYD* is the most studied gene. More than 500 *DPYD* polymorphisms to date have been identified and have been linked to FP-related toxicity in cancer patients \[[@B22-jcm-09-02342],[@B37-jcm-09-02342],[@B38-jcm-09-02342],[@B39-jcm-09-02342],[@B40-jcm-09-02342],[@B41-jcm-09-02342],[@B42-jcm-09-02342],[@B43-jcm-09-02342],[@B44-jcm-09-02342],[@B45-jcm-09-02342]\]. Several of these variants are known to alter amino acid sequence or mRNA splicing, resulting in decreased enzymatic activity. Within the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, three variants (c.85T \> C (*DPYD\*9A*, p.C29R), c.1627A \> G (*DPYD\*5*, p.I543V), and c.2194G \> A (*DPYD\*6*, p.V732I)) are reported to have no effect on enzyme activity \[[@B46-jcm-09-02342]\]. Four variants that cause exon 14 skipping or amino acid substitution (c.1905 + 1G \> A (IVS14 + 1G \> A, *DPYD\*2A*), c.1679T \> G (*DPYD\*13*, p.I560S), c.1129 − 5923C \> G/hapB3, and c.2846A \> T (p.D949V)) are designated as having reduced enzymatic function and thus increase the risk of developing toxicity. Similarly, the Dutch Pharmacogenetics Working Group (DPWG) guidelines define these same four variants as risk factors for FP-related toxicity and recommend reducing treatment dosage when a patient possesses one of them \[[@B47-jcm-09-02342]\]. Although *DPYD\*9A*, *\*5*, and *\*6* are common variants in many ethnic groups, these four risk variants have not yet been identified in Asians \[[@B48-jcm-09-02342],[@B49-jcm-09-02342],[@B50-jcm-09-02342]\].

For most identified *DPYD* variants, except those mentioned above, the effect on DPD activity is unknown, and it is important to clarify the DPD phenotype \[[@B51-jcm-09-02342]\]. The current standard to predict DPD activity measures its enzymatic activity in PBMCs, which correlates with hepatic DPD activity \[[@B52-jcm-09-02342],[@B53-jcm-09-02342]\]. However, this method is not easily implemented in its current form in routine medical care, as it lacks solid evidence of clinical utility. Due to insufficient sensitivity, methods for quantifying pyrimidine metabolites in blood or urine might not identify patients with partial DPD deficiencies \[[@B23-jcm-09-02342]\]. Moreover, additional studies on the clinical validity and utility of these tests are required before implementation can be justified.

In vitro testing is one of the methods used for estimating DPD phenotypes and for the functional analysis of identified non-synonymous variants \[[@B54-jcm-09-02342],[@B55-jcm-09-02342],[@B56-jcm-09-02342],[@B57-jcm-09-02342],[@B58-jcm-09-02342],[@B59-jcm-09-02342],[@B60-jcm-09-02342]\]. Several studies of such tests using *E. coli* or mammalian cell expression systems have been reported ([Table 1](#jcm-09-02342-t001){ref-type="table"}). Ogura et al. functionally analyzed two variants (G366A and T768K) identified from 150 healthy Japanese volunteers using an *E. coli* expression system \[[@B57-jcm-09-02342]\]. Interestingly, while the G366A mutation produced a decreased intrinsic clearance (*CL~int~*) for 5-FU, reducing DPD activity by 50%, the T768K mutation did not. However, T768K-related activity decreased at a faster rate than that of wild-type DPD, suggesting protein instability. In a subsequent study, Offer et al. expressed 80 non-synonymous variants in HEK293T/c17 cells and measured their enzymatic activities using 5-FU as a substrate \[[@B58-jcm-09-02342]\]. M166V, E828K, K861R, and P1023T exhibited significantly higher activity than wild-type DPD. In contrast, 31 variants, including D949V, exhibited significantly lower activity than wild-type DPD. Elraiyah et al. also analyzed 10 non-synonymous variants identified from 588 Somali and Kenyan individuals using HEK293T/c17 cells \[[@B59-jcm-09-02342]\], in which P86L, P237L, A513V, T793I, V941A, and P1023S exhibited significantly reduced DPD activities. We have characterized 21 DPD allelic variants identified from 1070 Japanese individuals by transient expression in 293FT cells \[[@B60-jcm-09-02342]\]. Among these, 10 (T298M, V313L, V335M, A380V, V434L, V515I, R592W, T768K, H807R, and V826M) showed significantly reduced *CL~int~* values relative to wild-type DPD, and the 5-FU metabolic activity of G926V was practically zero. These reports have yielded consistent results for *DPYD\*2A*, which exhibited decreased activity, and for *DPYD\*5* (I543V) and *\*6* (V732I), which exhibited activities that were not considerably different from that of wild-type DPD. In contrast, there are variants such as *DPYD\*9A* (C29R) and M166V, whose reported activities differ significantly among previous reports. Ogura et al. and our group found that M166V had a lower activity compared with that of wild-type DPD, while Offer et al. reported a reduction in activity for M166V. The differences in these activities are believed to be due to the differences in assay conditions and cell lines used. Notably, we and Ogura et al. reported DPD variants that were identified almost exclusively in Japanese individuals. Therefore, this raises awareness of the possibility of unidentified rare and relevant ethno-specific variants, which could lead to severe FP-related toxicity.

From a biochemical perspective, human DPD is a flavoprotein containing a single flavin mononucleotide (FMN), a single flavin adenine dinucleotide (FAD), and four iron-sulfur (FeS) clusters. Human DPD consists of five major domains \[[@B61-jcm-09-02342],[@B62-jcm-09-02342],[@B63-jcm-09-02342],[@B64-jcm-09-02342]\]. Domain I (residues 27--172) and domain V (residues 1--26, 848--1025) each contain two FeS clusters. FAD- and nicotinamide adenine dinucleotide phosphate (NADPH)-binding sites are located in domain II (residues 173--286, 442--524) and domain III (residues 287--441), respectively. FMN and the substrate both bind to domain IV (residues 525--847). Human DPD form a dimer, in which electrons from NADPH are transferred to the FeS clusters to catalyze the reduction of bound substrates \[[@B65-jcm-09-02342]\]. Domains II and IV are essential for DPD activity in the structural analysis of variants. Amino acid substitutions that have been observed to affect protein conformation adjacent to the FeS clusters have also caused a significant decrease in enzyme activity.

Henricks et al. described a prediction method using an activity score system and divided *DPYD* alleles into three categories, consisting of fully functional alleles (wild-type; value of 1), reduced activity alleles (c.2846A \> T and HapB3; value of 0.5), and nonfunctional alleles (*DPYD\*2A* and *\*13*; value of 0) \[[@B66-jcm-09-02342]\]. Allele values are totaled for a given patient, leading to an individual gene activity score that represents the DPD phenotype of the patient. Moreover, Shrestha et al. developed a *DPYD*-specific variant classifier (*DPYD*-Varifier) using machine learning of in vitro functional data from 156 variants \[[@B67-jcm-09-02342]\]. This model exhibited an accuracy of 85% and outperformed other in silico prediction tools, including PROVEAN, SIFT, and Polyphen-2. In the future, it may be possible to easily predict in vivo DPD activity using machine learning by creating compound databases by gathering detailed information from in vitro analyses. Recently, a list of *DPYD* variants has been added to the Pharmacogene Variation Consortium website (<https://www.pharmvar.org/gene/DPYD>). It is expected that evidence-based decisions on FP therapeutic regimens and patient-specific dose guidelines could be applied on the basis of an activity score formula, as has been recommended and implemented with other clinically relevant metabolic enzymes.

3. Dihydropyrimidinase (DHP) {#sec3-jcm-09-02342}
============================

DHP, as previously mentioned, catalyzes the hydrolytic ring opening of FUH~2~ and UH~2~ and is expressed mainly in the liver and kidneys \[[@B15-jcm-09-02342],[@B68-jcm-09-02342]\]. The human DHP gene (*DPYS)* consists of 10 exons mapped to chromosome 8q22, and features a 1560 bp open reading frame, corresponding to a 519 amino acid protein \[[@B17-jcm-09-02342]\].

DHP deficiency is an autosomal recessive disease characterized by the accumulation of UH~2~ and dihydrothymine (TH~2~) in blood, urine, and cerebrospinal fluid \[[@B69-jcm-09-02342]\]. The clinical phenotype of DHP-deficient patients is highly variable, ranging from asymptomatic to exhibiting symptomatology similar to that of DPD deficiency, including seizures, intellectual disability, growth impairment, and dysmorphic facial features \[[@B70-jcm-09-02342],[@B71-jcm-09-02342],[@B72-jcm-09-02342]\]. To date, 35 genetically confirmed patients with DHP deficiency have been reported \[[@B33-jcm-09-02342],[@B73-jcm-09-02342],[@B74-jcm-09-02342],[@B75-jcm-09-02342],[@B76-jcm-09-02342],[@B77-jcm-09-02342]\]. However, potential asymptomatic deficiencies might be present in a population with a low frequency of DPD deficiencies. In screening 21,200 healthy Japanese infants, Sumi et al. estimated the deficiency frequency to be approximately 1/10,000 \[[@B73-jcm-09-02342]\]. Akai et al. analyzed the *DPYS* coding regions from 183 Japanese individuals, in which the c.349T \> C (p.W117R) and c.1001A \> G (p.Q334R) variants were identified with an allelic frequency of 0.27% and 1.09%, respectively \[[@B78-jcm-09-02342]\].

To date, multiple studies have reported on the relationship between DPD deficiency and the risk of developing FP-related toxicity. However, there is an increasing awareness that patients with DHP deficiencies are also prone to the development of severe FP-associated toxicity. One such study identified severe FP-related toxicity in a female breast cancer patient with the *DPYS* heterozygous mutation c.833G \> A (p.G278D) \[[@B21-jcm-09-02342]\]. We previously reported about a patient with severe capecitabine-associated toxicity and DHP deficiency caused by a compound *DPYS* heterozygous mutation, c.1001A \> G (p.Q334R) and c.1393C \> T (p.R465X), including a genetic analysis of the patient's family \[[@B79-jcm-09-02342]\]. Urinary pyrimidine analysis of the patient's family revealed that the UH~2~/uracil ratio of heterozygous individuals was similar to that of wild-type individuals. Although heterozygous patients are predominantly asymptomatic, severe toxicity might occur during chemotherapy containing FPs, rendering the need for genetic testing before FP administration \[[@B80-jcm-09-02342]\].

It is noteworthy that a sizable number of DHP-deficient patients have been identified in East Asian populations. Hamajima et al. identified a single frameshift mutation and five *DPYS* missense variants in six Japanese patients with dihydropyrimidinuria \[[@B17-jcm-09-02342]\]. Nakajima et al. reported two Chinese pediatric patients with DHP deficiency caused by the compound *DPYS* heterozygous mutation c.1001A \> G and c.1443 + 5G \> A (exon 8 skipping) \[[@B81-jcm-09-02342]\]. Moreover, Nakajima et al. identified eight variants, including four novel missense mutations and one novel deletion in four DHP-deficient patients \[[@B77-jcm-09-02342]\]. Thus, *DPYS* polymorphisms could emerge as novel pharmacogenomic markers associated with severe FP-related toxicity in diverse global populations.

Recently, in vitro functional characterization of DHP variants using heterologous expression systems, including *E. coli* and mammalian cells, has been reported ([Table 2](#jcm-09-02342-t002){ref-type="table"}). Van Kuilenburg et al. reported that in the case of 14 variants (L7V, M70T, D81G, G278D, R302Q, L337P, T343A, W360R, V364M, S379R, R412M, R465X, R475X, and R490C) expressed in *E. coli*, the hydrolytic ring opening of radiolabeled UH~2~ was markedly altered \[[@B71-jcm-09-02342],[@B76-jcm-09-02342]\]. Hamajima et al. and Thomas et al. reported that six variants (L7V, T68R, Q334R, W360R, G435R, and R490C) showed lower activities than wild-type DHP in COS-7 and RKO cells expression systems \[[@B17-jcm-09-02342],[@B82-jcm-09-02342]\]. We have characterized 21 DHP variants and wild-type DHP expressed in 293FT cells using UH~2~ and FUH~2~ as substrates \[[@B83-jcm-09-02342]\]. Among these, 13 variants (N16K, T68R, M70T, D81G, G278D, R302Q, L337P, W360R, S379R, G435R, R465X, R475X, and R490C) demonstrated no enzymatic activity, and five variants (W117R, Q334R, T343A, V364M, and R412M) showed significantly lower *CL~int~* values than wild-type DHP. Except for L7V, the results of this study corroborated those of other in vitro studies, suggesting that the specific experimental conditions reflected the in vivo activities of the assayed variants. The divergence observed for L7V might be due to differences in assay conditions, substrate concentrations, or expression systems used.

Hsieh et al. reported that dimer formation is essential for DHP activity \[[@B84-jcm-09-02342]\]. Within the cell, DHP is known to form a tetramer composed of subunits containing two zinc ions each \[[@B85-jcm-09-02342],[@B86-jcm-09-02342],[@B87-jcm-09-02342]\]. Each DHP subunit consists of two domains, a large (β/α)~8~-barrel domain that binds the catalytic dimetal center and a small β-sandwich domain \[[@B88-jcm-09-02342]\]. Each subunit also has two dynamic loops, which act as a lid for the substrate-binding pocket. DHP activity is exerted by the interaction of the C-terminus with the dynamic loop of the neighboring subunit \[[@B89-jcm-09-02342],[@B90-jcm-09-02342],[@B91-jcm-09-02342]\]. We have performed immunoblotting assays of native proteins following blue native polyacrylamide gel electrophoresis and showed that oligomer formation is very important for DHP activity \[[@B83-jcm-09-02342]\]. In the reduced or null-activity variants, the ability of DHP to form oligomers was reduced. The five variants G435R, R465X, R475X, R490C, and R490H introduce mutations in the C-terminus or lead to truncation of the C-terminus, thus affecting oligomer formation and resulting in loss of enzymatic activity. In contrast, the substitutions T68R, M70T, D81G, W117R, M250I, G278D, R302Q, Q334R, L337P, T343A, and R412M exist near the active site of the two dynamic loops, which result in conformational changes in the active site that reduce or eliminate activity. Thus, it has been clarified that changes in DHP activity are associated with amino acid substitutions, as well as changes in oligomer formation and the resulting three-dimensional structure. DHP deficiencies are rarely reported in Caucasians but are highly prevalent in Asians. Thus, we consider that these variants could serve as novel pharmacogenomic markers for the prevention of FP-related toxicity, especially in populations that have a low frequency of symptomatic DPD-deficiency cases.

4. β-Ureidopropionase (β-UP) {#sec4-jcm-09-02342}
============================

β-UP catalyzes the irreversible last step, converting FUPA and β-ureidopropionic acid (bUPA) to fluoro-β-alanine and β-alanine, respectively. The human β-UP gene, *UPB1*, is located on chromosome 22q11, contains 10 exons, and features an 1155 bp open reading frame; the gene encodes a polypeptide containing 384 amino acids \[[@B18-jcm-09-02342]\]. Human β-UP activity has been detected predominantly in the liver and kidney \[[@B26-jcm-09-02342],[@B92-jcm-09-02342]\].

β-UP deficiency is an autosomal recessive disease characterized by the accumulation of bUPA and *N*-carbamoyl-β-aminoisobutyric acid (NCBA) in urine, blood, and cerebrospinal fluid \[[@B93-jcm-09-02342],[@B94-jcm-09-02342]\]. To date, 33 genetically confirmed patients with β-UP deficiency have been reported \[[@B94-jcm-09-02342],[@B95-jcm-09-02342],[@B96-jcm-09-02342],[@B97-jcm-09-02342],[@B98-jcm-09-02342],[@B99-jcm-09-02342],[@B100-jcm-09-02342]\]. The clinical phenotype of these patients is highly variable but tends to center around neurological problems. Similar to DHP deficiency, β-UP deficiency is often reported in East Asian populations, including Japan and China. Although it has been reported that severe FP-related toxicity is caused by DPD and DHP deficiencies, little is known about the relationship between β-UP deficiency and FP-related toxicity.

There have been several reports of the in vitro analysis of 13 *UPB1* variants with amino acid substitutions identified in β-UP-deficient patients ([Table 3](#jcm-09-02342-t003){ref-type="table"}). Van Kuilenburg et al. and Thomas et al. reported that variant A85E expressed in *E. coli* and RKO cells was inactive \[[@B93-jcm-09-02342],[@B101-jcm-09-02342]\]. In a separate study, van Kuilenburg et al., using an *E. coli* expression system, analyzed six β-UP variants (L13S, G235R, R236W, S264R, R326Q, and T359M) that had been previously identified in 16 β-UP-deficient patients, showing a significant reduction or loss of activity in all of them \[[@B95-jcm-09-02342]\]. Nakajima et al. reported that the G31S, E271K, and R326Q variants expressed in HEK293 cells showed profound reductions in activity \[[@B97-jcm-09-02342]\]. Moreover, Nakajima et al. performed native polyacrylamide gel electrophoresis of β-UP expressed in HEK293 cells and showed that octamer formation is necessary for β-UP activity as well as DHP activity. The majority of variants showed a significant reduction in enzymatic activity. However, whether these variants contribute to the development of FP-related toxicity remains unclear.

Fidlerova et al. performed an analysis of the entire *UPB1* coding sequence from 113 Czech cancer patients treated using FP-based chemotherapy \[[@B102-jcm-09-02342]\]. Nine *UPB1* variants were detected in a subpopulation of patients exhibiting severe toxicity, including a novel mutation affecting the coding sequence. An analysis of the effect of *UPB1* variants on FP-related toxicity in the population of all analyzed patients revealed an association between the c.−80C \> G (rs2070474) variant and gastrointestinal toxicity. In addition, a strong positive correlation was found between carriers of the homozygous c.−80G variant and the development of severe mucositis. Thomas et al. deduced that the c.−80G variants might alter the potential binding sites of transcription factors, resulting in a statistically non-significant decrease in *UPB1* gene expression in patients who are homozygous for the c.−80G allele. This indicates the possibility that *UPB1* variants have an additive and relatively minor effect on the development of FP-related toxicity compared with that of the *DPYD* and *DPYS* variants.

5. Other Considerations {#sec5-jcm-09-02342}
=======================

Genetic variations in TYMS, MTHFR, and miR-27a have also been associated with FP-related toxicity. Clinical and preclinical studies have shown the importance of intracellular levels of TYMS, a target for 5-FU involved in DNA repair and synthesis \[[@B103-jcm-09-02342]\], as a determinant of sensitivity to 5-FU treatment. Its overexpression stemming from polymorphic TYMS variations lead to differing response rates to 5-FU therapy \[[@B104-jcm-09-02342]\]. The three most studied TYMS genetic polymorphisms are the variable numbers of tandem repeat (VNTR) polymorphisms comprising 28 bp sequence repeats (rs34743033), rs2853542C \> G, and the 3'-untranslated region polymorphism 1494delTTAAAG (rs34489327). These polymorphisms alter gene expression, mRNA stability, or TYMS expression levels, resulting in the development of treatment resistance and toxicity \[[@B105-jcm-09-02342],[@B106-jcm-09-02342],[@B107-jcm-09-02342]\]. MTHFR plays a role in the metabolism of folate and forms the reduced folate cofactor essential for TYMS inhibition by 5-FU. Two non-synonymous variants, c.677C \> T (p.A222V, rs1801133) and c.1298A \> C (p.E429A, rs1801131), alter intracellular folate distribution and decrease enzymatic activity \[[@B105-jcm-09-02342],[@B107-jcm-09-02342]\]. The micro RNA miR-27a polymorphism (rs895819A \> G) has been associated with FP-related toxicity, more so in DPD-deficient patients, as increased miR-27a expression leads to decreased DPD mRNA expression \[[@B108-jcm-09-02342],[@B109-jcm-09-02342],[@B110-jcm-09-02342]\]. To date, however, studies involving these genetic polymorphisms have yielded inconsistent results, and further assessment is needed to assess their clinical utility and potential use as biomarkers.

6. Conclusions {#sec6-jcm-09-02342}
==============

FPs are degraded by three metabolic enzymes (DPD, DHP, and β-UP), and a reduction or elimination of their activities leads to severe FP-related toxicity. Therefore, predicting enzymatic activity is critical before the administration of FPs, in which in vitro testing has proven to be a useful complementary method to in vivo testing. This review summarized the findings on the functional characterization of DPD, DHP, and β-UP using in vitro analysis. To date, a large number of DPD variants have been analyzed, giving rise to a significant body of evidence regarding the four most commonly identified risk variants in Caucasians (*DPYD\*2A*, *DPYD\*13*, c.1129 − 5923C \> G/hapB3, and c.2846A \> T) that are associated with an increased risk of 5-FU-related toxicity. Additionally, a system for predicting in vivo DPD activity has been developed on the basis of in vitro analysis results. This has provided further evidence that rare DHP variants might be useful predictive biomarkers of FP-related toxicity in populations with low frequencies of DPD deficiency, as is the case for Asians. Notably, β-UP is not known to be associated with FP-related toxicity, although variants with reduced function have been identified. Currently, studies comprising in vivo and in vitro correlation of frequent *DPYD* polymorphisms are advancing applicability as well as underlying the importance of including infrequent *DPYD*, *DPYS*, and *UPB1* variants, as their collective data is insufficient to establish their clinical consequences fully. Additional in vitro and large-scale in vivo studies using standardized methodologies are needed to generate clear evidence for rare variants and verify existing associative studies.

Recently, the underlying mechanisms by which amino acid substitutions alter enzymatic activities by influencing three-dimensional structures have been elucidated; these findings have significant implications toward the interpretation of previously acquired data and how they could be further used to aid clinical decision making for optimal treatments and forewarning the need for alternative chemotherapy regimens. We expect that this report and others related to genetic FP-metabolizing enzyme variants will be useful in the development and further validation of pharmacogenetic testing with the future inclusion of additional biomarkers. In this way, these developments could lead to optimal personalized medicine grounded on genetic polymorphisms.
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![Uracil and 5-fluorouracil degradation pathway. Uracil and 5-fluorouracil are catabolized successively by dihydropyrimidine dehydrogenase, dihydropyrimidinase, and β-ureidopropionase. β-Alanine and fluoro-β-alanine are the final metabolites in this pathway.](jcm-09-02342-g001){#jcm-09-02342-f001}
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###### 

*DPYD* variants reported in in vitro analysis.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  dbSNP rsID     PharmVar ID   Location    Nucleotide Change             Amino Acid Substitution   Domain   Expression System    Substrates   Effect                     References
  -------------- ------------- ----------- ----------------------------- ------------------------- -------- -------------------- ------------ -------------------------- --------------------------
  rs150036960    PV00901       Exon 2      46C \> G                      L16V                      V        HEK293T/c17          5-FU         Normal function            \[[@B58-jcm-09-02342]\]

  rs72549310     PV01042       Exon 2      61C \> T                      R21X                      I        HEK293T/c17          5-FU         No function                \[[@B58-jcm-09-02342]\]

  rs80081766     PV01307       Exon 2      62G \> A                      R21Q                      I        HEK293T/c17          5-FU         Normal function            \[[@B58-jcm-09-02342]\]

  --             --            Exon 2      74A \> G                      H25R                      I        293FT                5-FU         156% of *CL~int~* ratio    \[[@B60-jcm-09-02342]\]

  rs1801265      PV00910       Exon 2      85T \> C (*DPYD\*9A*)         C29R                      I        HEK293T/c17\         5-FU\        Increased function\        \[[@B54-jcm-09-02342]\]\
                                                                                                            HEK293 Flp-In        Thymine      Decreased function         \[[@B55-jcm-09-02342]\]

  rs371587702    PV00962       Exon 3      194C \> T                     T65M                      I        HEK293T/c17          5-FU         Normal function            \[[@B58-jcm-09-02342]\]

  --             --            Exon 4      257C \> T                     P86L                      I        HEK293T/c17          5-FU         No function                \[[@B59-jcm-09-02342]\]

  rs143986398    PV00887       Exon 4      274C \> G                     P92A                      I        HEK293T/c17          5-FU         Decreased function         \[[@B58-jcm-09-02342]\]

  rs72549309     PV01041       Exon 4      295delTCAT\                   F100fs                    I        HEK293T/c17          5-FU         No function                \[[@B58-jcm-09-02342]\]
                                           (*DPYD\*7*)                                                                                                                   

  rs150385342    PV00902       Exon 4      313G \> A                     A105T                     I        HEK293T/c17          5-FU         Normal function            \[[@B58-jcm-09-02342]\]

  --             --            Exon 5      325T \> A                     Y109N                     I        293FT                5-FU         79% of *CL~int~* ratio     \[[@B60-jcm-09-02342]\]

  rs141462178    PV00878       Exon 5      343A \> G                     M115V                     I        HEK293T/c17          5-FU         Normal function            \[[@B58-jcm-09-02342]\]

  rs200562975    PV00927       Exon 5      451A \> G                     N151D                     I        293FT\               5-FU\        107% of *CL~int~* ratio\   \[[@B60-jcm-09-02342]\]\
                                                                                                            HEK293T/c17          5-FU         Normal function            \[[@B58-jcm-09-02342]\]

  rs2297595      PV0943        Exon 6      496A \> G                     M166V                     I        293FT\               5-FU\        77% of *CL~int~* ratio\    \[[@B60-jcm-09-02342]\]\
                                                                                                            HEK293T/c17\         5-FU\        Increased function\        \[[@B58-jcm-09-02342]\]\
                                                                                                            HEK293 Flp-In        Thymine      Decreased function         \[[@B55-jcm-09-02342]\]

  rs139834141    PV00871       Exon 6      498G \> A                     M166I                     I        HEK293T/c17          5-FU         Normal function            \[[@B58-jcm-09-02342]\]

  rs371792178    --            Exon 6      524C \> T                     S175L                     II       293FT                5-FU         131% of *CL~int~* ratio    \[[@B60-jcm-09-02342]\]

  rs115232898    PV00862       Exon 6      557A \> G                     Y186C                     II       HEK293T/c17          5-FU         Decreased function         \[[@B58-jcm-09-02342]\]

  rs72549308     PV01040       Exon 6      601A \> C                     S201R                     II       HEK293T/c17          5-FU         No function                \[[@B58-jcm-09-02342]\]

  rs72549307     PV01039       Exon 6      632A \> G                     Y211C                     II       HEK293T/c17          5-FU         Decreased function         \[[@B58-jcm-09-02342]\]

  rs1801266      PV00911       Exon 7      703C \> T\                    R235W                     II       HEK293T/c17          5-FU         Decreased function         \[[@B58-jcm-09-02342]\]
                                           (*DPYD\*8*)                                                                                                                   

  rs780025995    PV01299       Exon 7      710C \> T                     P237L                     II       HEK293T/c17          5-FU         Decreased function         \[[@B59-jcm-09-02342]\]

  rs45589337     PV00984       Exon 8      775A \> G                     K259E                     II       HEK293T/c17          5-FU         Normal function            \[[@B58-jcm-09-02342]\]

  rs777220476    PV01275       Exon 9      851G \> T                     G284V                     II       HEK293 Flp-In        Thymine      No function                \[[@B56-jcm-09-02342]\]

  rs146356975    PV00895       Exon 9      868A \> G                     K290E                     III      HEK293T/c17          5-FU         Decreased function         \[[@B58-jcm-09-02342]\]

  rs143878757    PV00886       Exon 9      893C \> T                     T298M                     III      293FT                5-FU         50% of *CL~int~* ratio     \[[@B60-jcm-09-02342]\]

  rs183105782    PV00914       Exon 9      910T \> C                     Y304H                     III      HEK293T/c17          5-FU         Decreased function         \[[@B58-jcm-09-02342]\]

  rs150437414    PV00904       Exon 9      929T \> C                     L310S                     III      HEK293T/c17          5-FU         Normal function            \[[@B58-jcm-09-02342]\]

  rs145112791    PV00891       Exon 9      934C \> T                     L312F                     III      HEK293T/c17          5-FU         Normal function            \[[@B58-jcm-09-02342]\]

  --             --            Exon 9      937G \> T                     V313L                     III      293FT                5-FU         30% of *CL~int~* ratio     \[[@B60-jcm-09-02342]\]

  rs201018345    PV00933       Exon 10     967G \> A                     A323T                     III      HEK293T/c17          5-FU         Normal function            \[[@B58-jcm-09-02342]\]

  rs72549306     PV01038       Exon 10     1003G \> A                    V335M                     III      293FT                5-FU         47% of *CL~int~* ratio     \[[@B60-jcm-09-02342]\]

  rs72549306     PV01037       Exon 10     1003G \> T\                   V335L                     III      HEK293T/c17          5-FU         Normal function            \[[@B58-jcm-09-02342]\]
                                           (*DPYD\*11*)                                                                                                                  

  rs183385770    PV00915       Exon 10     1024G \> A                    D342N                     III      HEK293T/c17          5-FU         Decreased function         \[[@B58-jcm-09-02342]\]

  rs190577302    PV00919       Exon 10     1054C \> G                    L352V                     III      HEK293T/c17          5-FU         Decreased function         \[[@B58-jcm-09-02342]\]

  rs143154602    PV00882       Exon 10     1057C \> T                    R353C                     III      HEK293T/c17          5-FU         No function                \[[@B58-jcm-09-02342]\]

  --             --            Exon 10     1097G \> C                    G366A                     III      293FT\               5-FU\        71% of *CL~int~* ratio\    \[[@B60-jcm-09-02342]\]\
                                                                                                            *Escherichia coli*   5-FU         47% of *CL~int~* ratio     \[[@B57-jcm-09-02342]\]

  rs72549305     PV01036       Exon 10     1108A \> G                    I370V                     III      HEK293T/c17          5-FU         Normal function            \[[@B58-jcm-09-02342]\]

  --             --            Exon 11     1139C \> T                    A380V                     III      293FT                5-FU         33% of *CL~int~* ratio     \[[@B60-jcm-09-02342]\]

  --             --            Exon 11     1150A \> G                    K384E                     III      293FT                5-FU         68% of *CL~int~* ratio     \[[@B60-jcm-09-02342]\]

  rs78060119     PV01302       Exon 11     1156G \> T(*DPYD\*12*)        E386X                     III      HEK293T/c17          5-FU         No function                \[[@B58-jcm-09-02342]\]

  rs140602333    PV00874       Exon 11     1180C \> T                    R394W                     III      HEK293T/c17          5-FU         Normal function            \[[@B58-jcm-09-02342]\]

  rs143815742    PV00883       Exon 11     1181G \> T                    R394L                     III      HEK293T/c17          5-FU         Normal function            \[[@B58-jcm-09-02342]\]

  rs143815742    PV00884       Exon 11     1181G \> A                    R394Q                     III      HEK293T/c17          5-FU         Normal function            \[[@B59-jcm-09-02342]\]

  --             --            Exon 11     1201G \> A                    G401R                     III      HEK293 Flp-In        Thymine      Decreased function         \[[@B55-jcm-09-02342]\]

  rs61622928     PV01018       Exon 11     1218G \> A                    M406I                     III      HEK293T/c17\         5-FU\        Normal function\           \[[@B58-jcm-09-02342]\]\
                                                                                                            HEK293 Flp-In        Thymine      Normal function            \[[@B55-jcm-09-02342]\]

  rs200064537    PV00925       Exon 11     1260T \> A                    N420K                     III      HEK293T/c17          5-FU         Normal function            \[[@B58-jcm-09-02342]\]

  rs764666241    PV0183        Exon 11     1278G \> T                    M426I                     III      HEK293T/c17          5-FU         Normal function            \[[@B58-jcm-09-02342]\]

  rs200693895    PV00931       Exon 11     1280T \> C                    V427A                     III      HEK293 Flp-In        Thymine      Normal function            \[[@B56-jcm-09-02342]\]

  rs142512579    PV00880       Exon 11     1294G \> A                    D432N                     III      HEK293T/c17          5-FU         Normal function            \[[@B58-jcm-09-02342]\]

  --             --            Exon 11     1300G \> C                    V434L                     III      293FT                5-FU         44% of *CL~int~* ratio     \[[@B60-jcm-09-02342]\]

  rs186169810    PV00916       Exon 11     1314T \> G                    F438L                     III      HEK293T/c17          5-FU         Decreased function         \[[@B58-jcm-09-02342]\]

  rs72975710     PV01043       Exon 12     1349C \> T                    A450V                     II       HEK293T/c17          5-FU         Normal function            \[[@B58-jcm-09-02342]\]

  rs144395748    PV00888       Exon 12     1358C \> G                    P453R                     II       HEK293T/c17          5-FU         Normal function            \[[@B58-jcm-09-02342]\]

  rs199549923    PV00921       Exon 12     1403C \> A                    T468N                     II       HEK293T/c17          5-FU         Normal function            \[[@B58-jcm-09-02342]\]

  rs72549304     PV01035       Exon 12     1475C \> T                    S492L                     II       HEK293T/c17          5-FU         Decreased function         \[[@B58-jcm-09-02342]\]

  rs111858276    PV00857       Exon 12     1484A \> G                    D495G                     II       HEK293T/c17          5-FU         Decreased function         \[[@B58-jcm-09-02342]\]

  rs138391898    PV00867       Exon 12     1519G \> A                    V507I                     II       HEK293T/c17          5-FU         Normal function            \[[@B58-jcm-09-02342]\]

  rs760663364    PV01150       Exon13      1538C \> T                    A513V                     II       HEK293T/c17          5-FU         Decreased function         \[[@B59-jcm-09-02342]\]

  rs148994843    PV00900       Exon 13     1543G \> A                    V515I                     II       293FT\               5-FU\        36% of *CL~int~* ratio\    \[[@B60-jcm-09-02342]\]\
                                                                                                            HEK293T/c17          5-FU         Normal function            \[[@B58-jcm-09-02342]\]

  --             --            Exon 13     1567C \> T                    L523F                     II       HEK293T/c17          5-FU         Normal function            \[[@B59-jcm-09-02342]\]

  rs190951787    PV00920       Exon 13     1577C \> G                    T526S                     IV       HEK293T/c17          5-FU         Normal function            \[[@B58-jcm-09-02342]\]

  rs1180771326   PV00864       Exon 13     1582A \> G                    I528V                     IV       HEK293T/c17          5-FU         Normal function            \[[@B59-jcm-09-02342]\]

  rs1801158      PV00907       Exon 13     1601G \> A (*DPYD\*4*)        S534N                     IV       HEK293T/c17\         5-FU\        Increased function\        \[[@B54-jcm-09-02342]\]\
                                                                                                            HEK293 Flp-In        Thymine      Decreased function         \[[@B55-jcm-09-02342]\]

  rs142619737    --            Exon 13     1615G \> C                    G539R                     IV       HEK293T/c17          5-FU         Normal function            \[[@B58-jcm-09-02342]\]

  rs1801159      PV00908       Exon 13     1627A \> G (*DPYD\*5*)        I543V                     IV       293FT\               5-FU\        102% of *CL~int~* ratio\   \[[@B60-jcm-09-02342]\]\
                                                                                                            HEK293T/c17\         5-FU\        Normal function\           \[[@B54-jcm-09-02342]\]\
                                                                                                            HEK293 Flp-In        Thymine      Normal function            \[[@B55-jcm-09-02342]\]

  rs55886062     PV01000       Exon 13     1679T \> G (*DPYD\*13*)       I560S                     IV       HEK293T/c17          5-FU         Decreased function         \[[@B54-jcm-09-02342]\]

  rs201615754    PV00937       Exon 13     1682G \> T                    R561L                     IV       HEK293T/c17          5-FU         Normal function            \[[@B58-jcm-09-02342]\]

  rs59086055     PV01015       Exon 14     1774C \> T                    R592W                     IV       293FT\               5-FU\        2% of *CL~int~* ratio\     \[[@B60-jcm-09-02342]\]\
                                                                                                            HEK293T/c17          5-FU         No function                \[[@B58-jcm-09-02342]\]

  rs138616379    PV00869       Exon 14     1775G \> A                    R592Q                     IV       HEK293T/c17          5-FU         Decreased function         \[[@B58-jcm-09-02342]\]

  rs145773863    PV00894       Exon 14     1777G \> A                    G593R                     IV       HEK293T/c17          5-FU         No function                \[[@B58-jcm-09-02342]\]

  rs147601618    PV00898       Exon 14     1796T \> C                    M599T                     IV       HEK293T/c17          5-FU         Normal function            \[[@B58-jcm-09-02342]\]

  Rs72549304     PV01034       Exon 4      1898delC\                     P633fs                    IV       HEK293T/c17          5-FU         No function                \[[@B58-jcm-09-02342]\]
                                           (*DPYD\*3*)                                                                                                                   

  rs3918289      PV00982       Exon 14     1905C \> T/G                  N635K                     IV       HEK293T/c17          5-FU         Normal function            \[[@B58-jcm-09-02342]\]

  rs3918290      PV00983       Intron 14   1905 + 1G \> A (*DPYD\*2A*)   Exon 14 skipping          IV       HEK293T/c17          5-FU         No function                \[[@B54-jcm-09-02342]\]

  rs55971861     PV01003       Exon 15     1906A \> C                    I636L                     IV       HEK293T/c17          5-FU         Normal function            \[[@B58-jcm-09-02342]\]

  rs138545885    PV00868       Exon 16     1990G \> T                    A664S                     IV       HEK293T/c17          5-FU         Normal function            \[[@B58-jcm-09-02342]\]

  rs137999090    PV00866       Exon 16     2021G \> A                    G674D                     IV       HEK293T/c17          5-FU         No function                \[[@B58-jcm-09-02342]\]

  --             --            Exon 17     2096G \> C                    R699T                     IV       HEK293T/c17          5-FU         Normal function            \[[@B59-jcm-09-02342]\]

  rs145548112    PV00893       Exon 17     2161G \> A                    A721T                     IV       HEK293T/c17          5-FU         Normal function            \[[@B58-jcm-09-02342]\]

  rs146529561    PV00896       Exon 18     2186C \> T                    A729V                     IV       HEK293T/c17          5-FU         Normal function            \[[@B58-jcm-09-02342]\]

  rs1801160      PV00909       Exon 18     2194G \> A (*DPYD\*6*)        V732I                     IV       293FT\               5-FU\        114% of *CL~int~* ratio\   \[[@B60-jcm-09-02342]\]\
                                                                                                            HEK293T/c17\         5-FU\        Normal function\           \[[@B54-jcm-09-02342]\]\
                                                                                                            HEK293 Flp-In        Thymine      Decreased function         \[[@B55-jcm-09-02342]\]

  rs60511679     PV01017       Exon 18     2195T \> G                    V732G                     IV       HEK293T/c17          5-FU         Normal function            \[[@B58-jcm-09-02342]\]

  rs112766203    PV00858       Exon 18     2279C \> T                    T760I                     IV       HEK293T/c17          5-FU         Decreased function         \[[@B58-jcm-09-02342]\]

  rs56005131     PV01004       Exon 19     2303C \> A                    T768K                     IV       293FT\               5-FU\        48% of *CL~int~* ratio\    \[[@B60-jcm-09-02342]\]\
                                                                                                            HEK293T/c17\         5-FU\        Normal function\           \[[@B58-jcm-09-02342]\]\
                                                                                                            *E. coli*            5-FU         83% of CLint ratio         \[[@B57-jcm-09-02342]\]

  rs199634007    PV00922       Exon 19     2336C \> A                    T779N                     IV       HEK293T/c17          5-FU         Normal function            \[[@B58-jcm-09-02342]\]

  rs547099198    PV00994       Exon 19     2378C \> T                    T793I                     IV       HEK293T/c17          5-FU         Decreased function         \[[@B59-jcm-09-02342]\]

  --             --            Exon 19     2420A \> G                    H807R                     IV       293FT                5-FU         50% of *CL~int~* ratio     \[[@B60-jcm-09-02342]\]

  --             --            Exon 20     2476G \> A                    V826M                     IV       293FT                5-FU         35% of *CL~int~* ratio     \[[@B60-jcm-09-02342]\]

  rs200687447    PV00930       Exon 20     2482G \> A                    E828K                     IV       HEK293T/c17          5-FU         Increased function         \[[@B58-jcm-09-02342]\]

  rs60139309     PV01016       Exon 20     2582A \> G                    K861R                     V        HEK293T/c17          5-FU         Increased function         \[[@B58-jcm-09-02342]\]

  rs201035051    PV00934       Exon 21     2623A \> C                    K875Q                     V        HEK293T/c17          5-FU         Normal function            \[[@B58-jcm-09-02342]\]

  rs55674432     PV00996       Exon 21     2639G \> T                    G880V                     V        HEK293T/c17          5-FU         No function                \[[@B58-jcm-09-02342]\]

  rs147545709    PV00897       Exon 21     2656C \> T                    R886C                     V        HEK293T/c17          5-FU         Normal function            \[[@B58-jcm-09-02342]\]

  rs1801267      PV00912       Exon 21     2657G \> A\                   R886H                     V        HEK293T/c17          5-FU         Normal function            \[[@B58-jcm-09-02342]\]
                                           (*DPYD\*9B*)                                                                                                                  

  rs188052243    PV00918       Exon 21     2678A \> G                    N893S                     V        293FT\               5-FU\        61% of *CL~int~* ratio\    \[[@B60-jcm-09-02342]\]\
                                                                                                            HEK293T/c17          5-FU         Decreased function         \[[@B58-jcm-09-02342]\]

  --             --            Exon 22     2777G \> T                    G926V                     V        293FT                5-FU         No function                \[[@B58-jcm-09-02342]\]

  --             --            Exon 22     2822T \> C                    V941A                     V        HEK293T/c17          5-FU         Decreased function         \[[@B59-jcm-09-02342]\]

  --             --            Exon 22     2843T \> C                    I948T                     V        HEK293 Flp-In        Thymine      Decreased function         \[[@B56-jcm-09-02342]\]

  rs67376798     PV01031       Exon 22     2846A \> T                    D949V                     V        HEK293T/c17\         5-FU\        Decreased function\        \[[@B58-jcm-09-02342]\]\
                                                                                                            HEK293 Flp-In        Thymine      Decreased function         \[[@B55-jcm-09-02342]\]

  rs141044036    PV00876       Exon 22     2872A \> G                    K958E                     V        HEK293T/c17          5-FU         No function                \[[@B58-jcm-09-02342]\]

  rs145529148    PV00892       Exon 23     2915A \> G                    Q972R                     V        HEK293T/c17          5-FU         Normal function            \[[@B58-jcm-09-02342]\]

  rs72547602     PV01033       Exon 23     2921A \> T                    D974V                     V        HEK293T/c17          5-FU         Normal function            \[[@B58-jcm-09-02342]\]

  rs72547601     PV01032       Exon 23     2933A \> G                    H978R                     V        HEK293T/c17          5-FU         No function                \[[@B58-jcm-09-02342]\]

  rs61757362     PV01019       Exon 23     2948C \> T                    T983I                     V        HEK293T/c17          5-FU         Decreased function         \[[@B58-jcm-09-02342]\]

  rs202144771    PV00941       Exon 23     2977C \> T                    L993F                     V        HEK293T/c17          5-FU         Normal function            \[[@B58-jcm-09-02342]\]

  rs139459586    PV00870       Exon 23     2978T \> G                    L993R                     V        HEK293T/c17          5-FU         Normal function            \[[@B58-jcm-09-02342]\]

  rs1801268      PV00913       Exon 23     2983G \> T\                   V995F                     V        HEK293T/c17          5-FU         No function                \[[@B58-jcm-09-02342]\]
                                           (*DPYD\*10*)                                                                                                                  

  rs140114515    PV00873       Exon 23     3049G \> A                    V1017I                    V        HEK293T/c17          5-FU         Normal function            \[[@B58-jcm-09-02342]\]

  rs148799944    PV00899       Exon 23     3061G \> C                    V1021L                    V        HEK293T/c17          5-FU         Normal function            \[[@B58-jcm-09-02342]\]

  rs114096998    PV00860       Exon 23     3067C \> A                    P1023T                    V        HEK293T/c17          5-FU         Normal function            \[[@B58-jcm-09-02342]\]

  rs114096998    PV00861       Exon 23     3067C \> T                    P1023S                    V        HEK293T/c17          5-FU         Decreased function         \[[@B59-jcm-09-02342]\]
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

jcm-09-02342-t002_Table 2

###### 

*DPYS* variants reported in in vitro analysis.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  dbSNP rsID    Location   Nucleotide Change   Amino Acid Substitution   Expression System   Substrates                      Effect                        References
  ------------- ---------- ------------------- ------------------------- ------------------- ------------------------------- ----------------------------- --------------------------
  rs199618701   Exon 1     17G \> A            R6Q                       293FT               FUH~2~                          120% of *CL~int~* ratio       \[[@B83-jcm-09-02342]\]

  rs57732538    Exon 1     19C \> G            L7V                       293FT\              FUH~2~UH~2~UH~2~                116% of *CL~int~* ratio\      \[[@B83-jcm-09-02342]\]\
                                                                         RKO\                                                65% of wild-type DHP\         \[[@B82-jcm-09-02342]\]\
                                                                         *E. coli*                                           No function                   \[[@B76-jcm-09-02342]\]

  rs572241599   Exon 1     48C \> G            N16K                      293FT               FUH~2~                          No function                   \[[@B83-jcm-09-02342]\]

  --            Exon 1     203C \> G           T68R                      293FT\              FUH~2~5-bromo-UH~2~             No function\                  \[[@B83-jcm-09-02342]\]\
                                                                         COS-7                                               1.5% of wild-type DHP         \[[@B17-jcm-09-02342]\]

  rs370718225   Exon 1     209T \> C           M70T                      293FT\              FUH~2~UH~2~                     No function\                  \[[@B83-jcm-09-02342]\]\
                                                                         *E. coli*                                           No function                   \[[@B76-jcm-09-02342]\]

  --            Exon 1     242A \> G           D81G                      293FT\              FUH~2~UH~2~                     No function\                  \[[@B83-jcm-09-02342]\]\
                                                                         *E. coli*                                           No function                   \[[@B76-jcm-09-02342]\]

  --            Exon 2     349T \> C           W117R                     293FT               FUH~2~                          44% of *CL~int~* ratio        \[[@B83-jcm-09-02342]\]

  rs36027551    Exon 3     541C \> T           R181W                     293FT\              FUH~2~UH~2~                     110% of *CL~int~* ratio\      \[[@B83-jcm-09-02342]\]\
                                                                         RKO                                                 99% of wild-type DHP          \[[@B82-jcm-09-02342]\]

  rs751371011   Exon 4     750G \> A           M250I                     HEK293              UH~2~                           2% of wild-type DHP           \[[@B77-jcm-09-02342]\]

  --            Exon 5     833G \> A           G278D                     293FT\              FUH~2~UH~2~                     No function\                  \[[@B83-jcm-09-02342]\]\
                                                                         *E. coli*                                           No function                   \[[@B21-jcm-09-02342]\]

  --            Exon 5     884A \> G           H295R                     HEK293              UH~2~                           9.8% of wild-type DHP         \[[@B77-jcm-09-02342]\]

  rs200913682   Exon 5     905G \> A           R302Q                     293FT\              FUH~2~UH~2~                     No function\                  \[[@B83-jcm-09-02342]\]\
                                                                         *E. coli*                                           3.9% of wild-type DHP         \[[@B76-jcm-09-02342]\]

  rs121964923   Exon 6     1001A \> G          Q334R                     293FT\              FUH~2~UH~2~5-bromo-UH~2~        20% of *CL~int~* ratio\       \[[@B83-jcm-09-02342]\]\
                                                                         HEK293\                                             9.7% of wild-type DHP\        \[[@B77-jcm-09-02342]\]\
                                                                         COS-7                                               2.5% of wild-type DHP         \[[@B17-jcm-09-02342]\]

  rs530911437   Exon 6     1010T \> C          L337P                     293FT\              FUH~2~UH~2~                     No function\                  \[[@B83-jcm-09-02342]\]\
                                                                         *E. coli*                                           No function                   \[[@B76-jcm-09-02342]\]

  rs201457190   Exon 6     1027A \> G          T343A                     293FT\              FUH~2~UH~2~                     43% of *CL~int~* ratio\       \[[@B83-jcm-09-02342]\]\
                                                                         *E. coli*                                           49% of wild-type DHP          \[[@B76-jcm-09-02342]\]

  rs121964924   Exon 6     1078T \> C          W360R                     293FT\              FUH~2~UH~2~UH~2~5-bromo-UH~2~   No function\                  \[[@B83-jcm-09-02342]\]\
                                                                         *E. coli*\                                          No function\                  \[[@B71-jcm-09-02342]\]\
                                                                         *E. coli*\                                          No function\                  \[[@B76-jcm-09-02342]\]\
                                                                         COS-7                                               1.2% of wild-type DHP         \[[@B17-jcm-09-02342]\]

  rs138282507   Exon 6     1090G \> A          V364M                     293FT\              FUH~2~UH~2~                     8% of *CL~int~* ratio\        \[[@B83-jcm-09-02342]\]\
                                                                         *E. coli*                                           No function                   \[[@B76-jcm-09-02342]\]

  rs201258823   Exon 7     1137C \> A          S379R                     293FT\              FUH~2~UH~2~                     No function\                  \[[@B83-jcm-09-02342]\]\
                                                                         *E. coli*                                           0.20--.9% of wild-type DHP    \[[@B76-jcm-09-02342]\]

  rs267606774   Exon 7     1235G \> T          R412M                     293FT\              FUH~2~UH~2~                     36% of *CL~int~* ratio\       \[[@B83-jcm-09-02342]\]\
                                                                         *E. coli*                                           No function                   \[[@B71-jcm-09-02342]\]

  --            Exon 8     1253C \> T          T418I                     HEK293              UH~2~                           64% of wild-type DHP          \[[@B77-jcm-09-02342]\]

  rs267606773   Exon 8     1303G \> A          G435R                     293FT\              FUH~2~5-bromo-UH~2~             No function\                  \[[@B83-jcm-09-02342]\]\
                                                                         COS-7                                               5.1% of wild-type DHP         \[[@B17-jcm-09-02342]\]

  rs201280871   Exon 8     1393C \> T          R465X                     293FT\              FUH~2~UH~2~                     No function\                  \[[@B83-jcm-09-02342]\]\
                                                                         *E. coli*                                           No function                   \[[@B76-jcm-09-02342]\]

  rs61758444    Exon 8     1423C \> T          R475X                     293FT\              FUH~2~UH~2~                     No function\                  \[[@B83-jcm-09-02342]\]\
                                                                         *E. coli*                                           0.2--0.9% of wild-type DHP    \[[@B76-jcm-09-02342]\]

  rs142574766   Exon 9     1468C \> T          R490C                     293FT\              FUH~2~UH~2~5-bromo-UH~2~        No function\                  \[[@B83-jcm-09-02342]\]\
                                                                         *E. coli*\                                          0.2--0.9% of wild-type DHP\   \[[@B76-jcm-09-02342]\]\
                                                                         COS-7                                               1.7% of wild-type DHP         \[[@B17-jcm-09-02342]\]

  Rs189448963   Exon 9     1469G \> A          R490H                     HEK293              UH~2~                           0.3% of wild-type DHP         \[[@B77-jcm-09-02342]\]
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

jcm-09-02342-t003_Table 3

###### 

*UPB1* variants identified in β-UP deficient patients.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  db SNP rsID    Location   Nucleotide Change   Amino Acid Substitution   Expression System              Substrates                Effect                   References
  -------------- ---------- ------------------- ------------------------- ------------------------------ ------------------------- ------------------------ --------------------------
  --             Exon 1     c.38T \> C          p.L13S                    *E. coli*                      bUPA                      6% of wild-type β-UP     \[[@B95-jcm-09-02342]\]

  rs200145797    Exon 1     c.91G \> A          p.G31S                    HEK293                         bUPA                      52% of wild-type β-UP    \[[@B97-jcm-09-02342]\]

  rs121908066    Exon 2     c.209G \> C         p.R70P                    No reports of in vitro study   \[[@B98-jcm-09-02342]\]                            

  rs34035085     Exon 2     c.254C \> A         p.A85E                    *E. coli*\                     bUPA\                     No function\             \[[@B93-jcm-09-02342]\]\
                                                                          RKO                            bUPA                      2.7% of wild-type β-UP   \[[@B101-jcm-09-02342]\]

  --             Exon 6     c.703G \> A         p.G235R                   *E. coli*                      bUPA                      No function              \[[@B95-jcm-09-02342]\]

  rs144135211    Exon 6     c.706C \> T         p.R236W                   *E. coli*                      bUPA                      No function              \[[@B95-jcm-09-02342]\]

  rs145766755    Exon 7     c.792C \> A         p.S264R                   *E. coli*                      bUPA                      20% of wild-type β-UP    \[[@B95-jcm-09-02342]\]

  --             Exon 7     c.811G \> A         p.E271K                   HEK293                         bUPA                      0.7% of wild-type β-UP   \[[@B97-jcm-09-02342]\]

  --             Exon 7     c.851G \> T         p.C284F                   No reports of in vitro study   \[[@B99-jcm-09-02342]\]                            

  rs1375840064   Exon 7     c.853G \> A         p.A285T                   No reports of in vitro study   \[[@B99-jcm-09-02342]\]                            

  --             Exon 7     c.857T \> C         p.I286T                   HEK293                         bUPA                      70% of wild-type β-UP    \[[@B97-jcm-09-02342]\]

  rs118163237    Exon 9     c.977G \> A         p.R326Q                   *E. coli*\                     bUPA\                     No function\             \[[@B95-jcm-09-02342]\]\
                                                                          HEK293                         bUPA                      1.3% of wild-type β-UP   \[[@B97-jcm-09-02342]\]

  rs369879221    Exon 10    c.1076C \> T        p.T359M                   *E. coli*                      bUPA                      No function              \[[@B95-jcm-09-02342]\]
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
